What is the clinical evidence from this study?

Study design: Review. Population: Cardiogenic shock. Intervention: Biologically informed phenotyping and biomarkers.

What does this research mean for the field?

Biomarker-driven phenotyping identifies distinct biological subphenotypes in cardiogenic shock, enabling improved risk stratification and targeted therapies beyond traditional clinical staging. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

This review aims to explore the biological heterogeneity of cardiogenic shock and the role of biomarkers in precision medicine.

May 24, 2026Current Opinion in Critical Care

Phenotyping and biomarkers in cardiogenic shock

View Full Paper

Ask AI

Bookmark

Key result

Biologically informed phenotyping improves cardiogenic shock risk stratification over traditional staging to guide targeted therapies.

Why the study?

Cardiogenic shock retains high mortality, and traditional staging systems fail to capture the marked biological heterogeneity underlying the condition.

Does biomarker-driven phenotyping improve risk stratification and characterization of biological heterogeneity in patients with cardiogenic shock compared to traditional staging systems?

Design

Review

Authors

SSSabri SoussiUniversity Health Network CJChristian JungDüsseldorf University Hospital HSH SchaubroeckGhent University Hospital

Discussion

Member takes

Implication

May support biomarker phenotyping for cardiogenic shock stratification; leaves open prospective validation before guiding therapy or trials.

Key Points

This review aims to explore the biological heterogeneity of cardiogenic shock and the role of biomarkers in precision medicine.
Review of recent findings related to biomarkers and biological pathways associated with cardiogenic shock.
Analysis of multimarker and omics-based studies combined with machine learning approaches.
Discussion on the integration of biomarker profiles with clinical assessments for improved classification.
Emerging subphenotypes identified through machine learning indicate distinct clinical trajectories.
Biomarkers reflect key domains, including myocardial injury and inflammation, critical for patient management.
Biologically informed phenotyping offers a framework for targeted therapies and clinical trial designs.

Structured PICO

Does biomarker-driven phenotyping improve risk stratification and characterization of biological heterogeneity in patients with cardiogenic shock compared to traditional staging systems?

Population

Patients with cardiogenic shock

Intervention

Biomarker-driven phenotyping (multimarker and omics-based approaches combined with machine learning)

Comparator

Traditional clinical staging systems

Outcome

Improved risk stratification and identification of biological subphenotypes

Biologically informed phenotyping using biomarkers and machine learning offers a framework for improved risk stratification and precision medicine in cardiogenic shock.

Cite This Study

Soussi et al. (2026) conducted a review in Cardiogenic shock. Biologically informed phenotyping and biomarkers was evaluated. Biologically informed phenotyping in cardiogenic shock enables improved risk stratification and offers a framework for future enriched clinical trial design and targeted therapies.

synapsesocial.com/papers/6a12959d48a0ea1665671c58 https://doi.org/10.1097/mcc.0000000000001388

View Full Paper

Ask AI

Bookmark

Implication

May support biomarker phenotyping for cardiogenic shock stratification; leaves open prospective validation before guiding therapy or trials.

Phenotyping and biomarkers in cardiogenic shock

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Phenotyping and biomarkers in cardiogenic shock

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider